In a trial for retatrutide, the average study participant lost 17.5 percent of their weight after 24 weeks and 24.2 percent after 48 weeks, Eli Lilly said in a June 26 news release. A placebo and the medication were administered subcutaneously in 338 adults who are overweight with a weight-related condition, not including Type 2 diabetes, or obese.
In comparison, an experimental pill version of Novo Nordisk’s Ozempic resulted in 15.1 percent weight loss in a phase 3 study, and an approved injectable drug for chronic weight management, Wegovy, trimmed the average person’s weight by 12.4 percent.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
